

References

I-235

1. Gampenrieder SP, Castagnaviz V, Rinnerthaler G, Greil R. Treatment landscape for patients with HER2-positive metastatic breast cancer: a review on emerging treatment options. *Cancer Management & Research*. 2020;12:10615-10629.
2. Bang YJ, Giaccone G, Im SA, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. *Annals of Oncology*. 2017;28(4):855-861.
3. Rugo HS, Im S-A, Cardoso F, et al. Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. *Clinical Advances in Hematology & Oncology*. 2020;18:15-17.
4. National Comprehensive Cancer Network (NCCN). Margetuximab. NCCN Drugs and Biologics Compendium®. 2021.
5. Margenza (Margetuximab), for intravenous use [package insert]. MacroGenics, Inc. Rockville, MD. Revised 12/2020.
6. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Margetuximab.
7. Micromedex DrugDex Compendium®. 2021. Margetuximab.
8. [Margetuximab] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2021.
9. Margetuximab. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.
10. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.